Park Place Capital’s Royalty Pharma RPRX Stock Holding History

Park Place Capital’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$167K	Hold	3,485	–	–	0.03%	205
2025 Q4	$135K	Hold	3,485	–	–	0.03%	220
2025 Q3	$123K	Hold	3,485	–	–	0.03%	230
2025 Q2	$125K	Hold	3,485	–	–	0.03%	247
2025 Q1	$108K	Buy	+3,485	New	+$110K	0.03%	248
2024 Q4	–	Sell	-3,753	Closed	-$106K	–	866
2024 Q3	$106K	Sell	3,753 -65	-2%	-$1.8K	0.03%	281
2024 Q2	$101K	Sell	3,818 -1,250	-25%	-$34.6K	0.03%	275
2024 Q1	$154K	Sell	5,068 -588	-10%	-$17.3K	0.06%	264
2023 Q4	$159K	Buy	5,656 +1,939	+52%	+$53.3K	0.06%	248
2023 Q3	$101K	Hold	3,717	–	–	0.03%	342
2023 Q2	$114K	Hold	3,717	–	–	0.03%	324
2023 Q1	$134K	Sell	3,717 -72	-2%	-$2.67K	0.04%	299
2022 Q4	$150K	Buy	+3,789	New	+$158K	0.04%	281

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Park Place Capital's RPRX Position: Q1 2026 in Review

Park Place Capital held its Royalty Pharma (RPRX) position steady in Q1 2026 at 3,485 shares worth $167K. The position accounts for 0.03% of the portfolio, ranked #205.

Park Place Capital first reported a position in RPRX in Q4 2022 and has held it in 13 quarters since. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

Park Place Capital held 3,485 shares of Royalty Pharma worth $167K as of Q1 2026.
Park Place Capital left its Royalty Pharma share count unchanged in Q1 2026.
Royalty Pharma made up 0.03% of Park Place Capital's portfolio in Q1 2026, its #205 holding.
Park Place Capital first reported a position in Royalty Pharma in Q4 2022 and has held it in 13 quarters since.
587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Park Place Capital's 13F filing for Q1 2026, filed 9 Apr 2026.